Gainers

• Catheter Precision (AMEX:VTAK) shares increased by 11.7% to $1.05 during Thursday's pre-market session. The market value of their outstanding shares is at $2.2 million. As per the press release, Q4 earnings came out 2 days ago.
• Cocrystal Pharma (NASDAQ:COCP) stock increased by 9.8% to $1.12. The company's market cap stands at $14.0 million. The company's, Q4 earnings came out 2 days ago.
• Intelligent Bio Solutions (NASDAQ:INBS) shares moved upwards by 8.97% to $3.4. The market value of their outstanding shares is at $6.2 million.
• Sionna Therapeutics (NASDAQ:SION) stock rose 8.95% to $45.0. The company's market cap stands at $1.8 billion.
• Profusa (NASDAQ:PFSA) shares moved upwards by 8.51% to $0.63.
• Century Therapeutics (NASDAQ:IPSC) stock moved upwards by 8.21% to $2.37. The company's market cap stands at $393.5 million.

Losers

• Inovio Pharmaceuticals (NASDAQ:INO) shares fell 21.3% to $1.37 during Thursday's pre-market session. The company's market cap stands at $120.2 million.
• CDT Equity (NASDAQ:CDT) stock declined by 20.59% to $4.05. The company's market cap stands at $24.0 million.
• Cyclerion Therapeutics (NASDAQ:CYCN) shares decreased by 20.07% to $5.1. The company's market cap stands at $24.2 million.
• HCW Biologics (NASDAQ:HCWB) shares decreased by 15.74% to $0.25. The company's market cap stands at $1.0 million. As per the news, the Q4 earnings report came out 2 days ago.
• Onconetix (NASDAQ:ONCO) shares fell 15.21% to $1.59. The market value of their outstanding shares is at $1.2 million.
• Enveric Biosciences (NASDAQ:ENVB) shares decreased by 13.83% to $1.84. The company's market cap stands at $2.9 million. As per the press release, Q4 earnings came out 4 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.